These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 16046552)
1. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552 [TBL] [Abstract][Full Text] [Related]
2. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Shi XH; Liang ZY; Ren XY; Liu TH Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633 [TBL] [Abstract][Full Text] [Related]
4. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo]. Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742 [TBL] [Abstract][Full Text] [Related]
5. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression. Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682 [TBL] [Abstract][Full Text] [Related]
6. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493 [TBL] [Abstract][Full Text] [Related]
7. Molecular target-based therapy of pancreatic cancer. Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047 [TBL] [Abstract][Full Text] [Related]
8. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596 [TBL] [Abstract][Full Text] [Related]
9. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Huang C; Jiang T; Zhu L; Liu J; Cao J; Huang KJ; Qiu ZJ Int J Oncol; 2011 Jun; 38(6):1637-44. PubMed ID: 21479358 [TBL] [Abstract][Full Text] [Related]
10. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer. Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338 [TBL] [Abstract][Full Text] [Related]
11. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Tokunaga T; Tsuchida T; Kijima H; Okamoto K; Oshika Y; Sawa N; Ohnishi Y; Yamazaki H; Miura S; Ueyama Y; Nakamura M Br J Cancer; 2000 Sep; 83(6):833-9. PubMed ID: 10952790 [TBL] [Abstract][Full Text] [Related]
12. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544 [TBL] [Abstract][Full Text] [Related]
13. Activation of Raf-1 in human pancreatic adenocarcinoma. Berger DH; Jardines LA; Chang H; Ruggeri B J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670 [TBL] [Abstract][Full Text] [Related]
14. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310 [TBL] [Abstract][Full Text] [Related]
15. MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Vidic S; Markelc B; Sersa G; Coer A; Kamensek U; Tevz G; Kranjc S; Cemazar M Cancer Gene Ther; 2010 Jun; 17(6):409-19. PubMed ID: 20094071 [TBL] [Abstract][Full Text] [Related]
16. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Qian J; Niu J; Li M; Chiao PJ; Tsao MS Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547 [TBL] [Abstract][Full Text] [Related]
17. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215 [TBL] [Abstract][Full Text] [Related]
18. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1. Fensterer H; Giehl K; Buchholz M; Ellenrieder V; Buck A; Kestler HA; Adler G; Gierschik P; Gress TM Genes Chromosomes Cancer; 2004 Mar; 39(3):224-35. PubMed ID: 14732924 [TBL] [Abstract][Full Text] [Related]
19. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Ramachandran V; Arumugam T; Hwang RF; Greenson JK; Simeone DM; Logsdon CD Cancer Res; 2007 Mar; 67(6):2666-75. PubMed ID: 17363587 [TBL] [Abstract][Full Text] [Related]
20. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer. Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]